Ethnic influences on stroke risk Francesco P Cappuccio MD MSc FRCP FFPH.

Slides:



Advertisements
Similar presentations
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
Advertisements

JNC 8 Guidelines….
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
UNIVERSITY OF CAMBRIDGE
Nancy R. Cook, ScD Championing Public Health Nutrition November 25-26, 2014 Sodium and Cardiovascular Health.
CVD risk estimation and prevention: An overview of SIGN 97.
Non-pharmacological prevention and management of hypertension: a global perspective F.P.Cappuccio MD MSc FRCP MFPH Cephalon Chair of Cardiovascular Medicine.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Advances and Controversies in Cardiovascular Risk Prediction Peter Brindle General Practitioner R&D lead Bristol, N.Somerset and S.Glouc PCTs Promises,
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
The concept of Diabetes & CV risk: A lifetime risk challenge
Hypertension: what is new…and old GREG FOTIEO, MD.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Hypertension.
Hypertension and The Older Patient
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
DR. IDOWU AKOLADE EDM DIVISION LUTH
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.
Simon Belderbos Consultant Psychiatrist
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
1 Current & New treatment strategies to address CV Risk.
Studying mortality trends: The IMPACT CHD Policy Model
Salt, Heart Disease, and Stroke Norm Campbell. 1) The role of increased blood pressure as a determinant of adverse outcomes 2) The health risks of high.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Fibrinogen in South Asians Dr Kirti Kain MD MRCP Academic Unit of Molecular Vascular Medicine Leeds University Leeds United Kingdom.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Objectives of Training To provide you with an overview of MSD Informatics Software. To provide you with sufficient training to be able to use MSD Informatics.
Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen
Cardiovascular Risk: A global perspective
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Antonio Coca, MD, PhD, FRCP, FESC
What should the Systolic BP treatment goal be in patients with CKD?
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Hypertension November 2016
The Anglo Scandinavian Cardiac Outcomes Trial
Risk factor thresholds: their existence under scrutiny
Teaching Tool: Blood Pressure Classification
Progress and Promise in RAAS Blockade
for the RODAM Consortium
2014 Update on Hypertension
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Primary Hypertension Max C. Reif, M.D.
Hypertension November 2016
Goals & Guidelines A summary of international guidelines for CHD
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
University College London
Presentation transcript:

Ethnic influences on stroke risk Francesco P Cappuccio MD MSc FRCP FFPH

2 Selected leading causes of death worldwide in 1990 Number of deaths (million) Lancet 1997;349: M (~70%) in developing countries

3 Prevalence of severe disability in men Age groups (per 1,000) Lancet 1997;349:

4 Ezzati M et al. Lancet 2002;360: Mortality due to leading global risk factors

5 Stroke is preventable! Time trends –rapid change in stroke mortality is likely to have resulted from change in incidence rates, so factors determining onset of disease must have changed

6 Trends in age-adjusted mortality from stroke in the US

7 Stroke is preventable! Time trends –rapid change in stroke mortality is likely to have resulted from change in incidence rates, so factors determining onset of disease must have changed Geographic variations –large international differences in stroke mortality –they are not fixed, e.g. in Japanese migrants

8 Prevalence of hypertension in populations of African origin (ICSHIB) R Cooper et al Am J Pub Health 1997; 87: Age and sex-adjusted prevalence (%) Prevalence of hypertension in populations of European vs African origin Age and sex-adjusted prevalence (%) R Cooper et al. BMC Medicine 2005; 3: 2

9 Mortality from Stroke amongst Japanese migrants Am J Epidemiol 1990;131: Deaths per 100,000 population

10 Stroke is preventable! Time trends –rapid change in stroke mortality is likely to have resulted from change in incidence rates, so factors determining onset of disease must have changed Geographic variations –large international differences in stroke mortality –they are not fixed, e.g. in Japanese migrants Causes of stroke –many can be avoided –effect reversible in a few years, e.g. RCTs

11 Results from a meta-analysis of 10 trials of anti-hypertensive drug therapy Total of 9278 active treatment and 9264 control patients

12 Risk Factors for Stroke Inherent biological traits –age, sex, ethnic background Physiological characteristics –blood pressure, fibrinogen, BMI, homocysteine, etc. Pathological factors –atrial fibrillation, diabetes, sickle cell disease Behaviour –smoking, diet, alcohol, OC Social characteristics –social class Environmental Features –temperature, season, etc. Genetics –candidate genes (AGT, Na-channel, G-protein, adducin,...)

13 Blood Pressure, Stroke and CHD

14 Variations by ethnic groups in the UK Burden of vascular disease Detection, management and control of hypertension Application of national guidelines Assessment of risk Non-drug therapy Pharmacological treatment

15 IHD and CVD Mortality in England & Wales (1983) in people aged yrs MenWomen S.M.R.% Balarajan R. BMJ 1991;302:560-4

16 Cause of death from vascular disease in US blacks and whites (1991 NYC Medical Examiner’s Office) MEN WOMEN (n=417) (n=170) ______________________________ Age at death (years)51.7 vs vs 61.5* Atherosclerotic0.4 ( )*0.4 ( )** Hypertensive2.2 ( )*3.1 ( )** Age-adjusted OR (95% CI) *p<0.01, **p<0.001 Hypertension 1998;31:1070-6

17 Incidence of first ever stroke in London (1995-6) Stewart JA et al. Br Med J 1999;318: yrs younger!

18 Infarct Large-vessel disease Multiple Infarcts Small-vessel disease Types of stroke Haemorrhage Intracerebral

19 Incidence of first ever stroke subtype in London (1995-6) Stewart JA et al. Br Med J 1999;318: *age-adjusted

20 Prevalence of hypertension * by age and ethnic group in South London African origin South Asian White African origin South Asian White *BP >160 and/or >95 mmHg or on therapy Heart 1997;78:555-63

21 Detection, Management and Control of Hypertension in S. London (1994-6) Inadequately treated 50.6% 49.4% 47.0% 10.1% 25.3% 13.4% 17.8% 13.5% 12.7% 21.5% 11.8% 26.9% Adequately treated Untreated Undetected Cappuccio FP et al. Heart 1997;78:555-63

22 Stroke Mortality and Quality of Hypertension Control Du et al. BMJ 1997 p<0.01 Adjusted Odds Ratios Cases 267 Controls 534 Average SBP achieved with Rx in last 5 yrs

23 Prevention and management of CVD based on overall absolute risk of disease, rather than individual risk factor management Recent guidelines now adopt this paradigm shift (JBS-2, BHS IV, NSF for CHD, NICE) Risk estimates based on 10-year prospective experience of Framingham cohort (sub-urban American white middle-class men and women) The burden of cardiovascular disease is not distributed equally among society. Ethnic groups have disproportionately high risk…but… Risk Assessment and Treatment Choices

24 Relationship between CHD and CVD risks by ethnic origin CHD overestimates CVD CHD under estimates CVD Cappuccio FP et al. Br Med J 2002;325: Sensitivity (%) 1.30 ( ) 1.40 ( ) 1.48 ( )

25 British evidence None prospective CHD and CVD risk by Framingham score not consistently related in ethnic groups [Cappuccio FP e al. BMJ 2002;325:1271-4] Discrepancies between predicted risks by ethnic group and SMR by country of birth [Quirke TP et al. Heart 2003;89:785-6] Inconsistent predictions between Framingham, FINRISK and SCORE in ethnic groups [Bhopal R et al. J Pub Health 2005;27:93-100] Age-adjustment to reduce inconsistency of Framingham risk across ethnic groups [Aarabi M et al. Eur J Cardiovasc Prev Rehab 2005;12:46-51]

26 ETHRISK A modified Framingham CHD and CVD risk calculator for British black and minority ethnic groups Heart 2006;92:

27 In people of African origin high blood pressure more common low plasma renin activity sensitive to changes in sodium intake sodium retention and volume expansion A slave trader licking a slave’s face to assess his fitness for the voyage across the Atlantic

28 BHS - NICE Guidelines

29 ALLHAT: blood pressure control* blacks vs non-blacks Wright JT et al. JAMA 2005;293: * % below 140/90 mmHg Chlorthalidone Amlodipine Lisinopril

30 ALLHAT: outcomes in blacks vs non-blacks Wright JT et al. JAMA 2005;293:

31 Stroke & ethnic minority groups Compared to whites, Africans & Caribbeans: have a lower incidence of CHD have a higher risk of stroke, renal failure and LVH BP more sensitive to salt restriction & benefit more from dietary advice alone low plasma renin and angiotensin  reduced response to ACE-i & ARBs (or  -blockers) as monotherapy – however, see ALLHAT Improved efficacy to ACE-inhibitors/ ARBs in combination with diuretics or CCBs Compared to whites, South Asians: have a greater incidence of CHD have also a higher risk of stroke and renal failure some sub-groups have high blood pressure and some have very high smoking rates metabolic abnormalities more common